Tetrazole derivatives
    2.
    发明授权
    Tetrazole derivatives 失效
    四唑衍生物

    公开(公告)号:US6121286A

    公开(公告)日:2000-09-19

    申请号:US158774

    申请日:1998-09-23

    CPC分类号: C07D401/14

    摘要: The present invention is directed to a tetrazole derivative represented by the following formula (1) or a salt thereof: ##STR1## wherein R.sup.1 and R.sup.2 independently represent a hydrogen atom, a hydroxyl group, a lower alkyl group, a substituted or unsubstituted alkoxy group, or a substituted or unsubstituted alkanoyloxy group; R.sup.3 represents a hydrogen atom or a substituted or unsubstituted lower alkyl group; A represents a methyleneoxy group or a vinylene group; B represents a substituted or unsubstituted quinolyl group, a substituted or unsubstituted quinazolyl group, or a substituted or unsubstituted benzimidazolyl group; and a broken line indicates that there may be a double bond; and to a medicine containing the compound as an active ingredient. The medicine according to the present invention is endowed with excellent antileukotriene activity and antihistaminic activity, and is useful for the prevention and treatment of, for example, asthma.

    摘要翻译: 本发明涉及由下式(1)表示的四唑衍生物或其盐:其中R1和R2独立地表示氢原子,羟基,低级烷基,取代或未取代的烷氧基或 取代或未取代的烷酰氧基; R3表示氢原子或取代或未取代的低级烷基; A表示亚甲氧基或亚乙烯基; B表示取代或未取代的喹啉基,取代或未取代的喹唑基,或取代或未取代的苯并咪唑基; 虚线表示可能存在双键; 和含有该化合物作为活性成分的药物。 根据本发明的药物具有优异的抗白三烯活性和抗组胺活性,可用于预防和治疗例如哮喘。

    Tetrazole derivatives
    3.
    发明授权
    Tetrazole derivatives 失效
    四唑衍生物

    公开(公告)号:US6117886A

    公开(公告)日:2000-09-12

    申请号:US357156

    申请日:1999-07-19

    CPC分类号: C07D401/14

    摘要: The present invention is directed to a tetrazole derivative represented by the following formula (1) or a salt thereof: ##STR1## wherein R.sup.1 and R.sup.2 independently represent a hydrogen atom, a hydroxyl group, a lower alkyl group, a substituted or unsubstituted alkoxy group, or a substituted or unsubstituted alkanoyloxy group; R.sup.3 represents a hydrogen atom or a substituted or unsubstituted lower alkyl group; A represents a methyleneoxy group or a vinylene group; Z represents a substituted or unsubstituted benzimidazolyl group; and a broken line indicates that there may be a double bond; and to a medicine containing the compound as an active ingredient. The medicine according to the present invention is endowed with excellent antileukotriene activity and antihistaminic activity, and is useful for the prevention and treatment of, for example, asthma.

    摘要翻译: 本发明涉及由下式(1)表示的四唑衍生物或其盐:其中R1和R2独立地表示氢原子,羟基,低级烷基,取代或未取代的烷氧基或 取代或未取代的烷酰氧基; R3表示氢原子或取代或未取代的低级烷基; A表示亚甲氧基或亚乙烯基; Z表示取代或未取代的苯并咪唑基; 虚线表示可能存在双键; 和含有该化合物作为活性成分的药物。 根据本发明的药物具有优异的抗白三烯活性和抗组胺活性,可用于预防和治疗例如哮喘。

    Diamine derivatives and pharmaceutical containing the same
    4.
    发明授权
    Diamine derivatives and pharmaceutical containing the same 失效
    二胺衍生物和含有相同的药物

    公开(公告)号:US6127360A

    公开(公告)日:2000-10-03

    申请号:US147777

    申请日:1999-03-05

    摘要: This invention relates to a diamine derivative represented by the following formula (1) or a salt thereof. wherein R.sup.1 represents H, OH, an aralkyloxy group or a halogen atom; R.sup.2 represents H or a lower alkyl group; A represents --C(R.sup.3).dbd.CH--, --CH.dbd.N--, --N(R.sup.4)--, R.sup.3 being H or OH, R.sup.4 being a lower alkyl group or an alkoxyalkyl group, --O--, or --S--; B represents a single bond, --C(R.sup.5)(R.sup.6)--(CH.sub.2).sub.k --, R.sup.5 and R.sup.6 being H or a lower alkyl group, and k being a value of from 0 to 2, --S(O).sub.q CH(R.sup.7), or --CH.dbd.CH--; E represents a single bond or --(CH.sub.2).sub.3 --; W and Y individually represent --CH.sub.2 -- or --CO--; Z represents O or S; and m is a value of 2 or 3, and n is a value of from 1 to 4; with the proviso that E is --(CH.sub.2).sub.3 -- when B is a single bond and E is a single bond when B is a group other than a single bond. The diamine derivatives or salts thereof have both antileukotrienic action and antihistaminic action and are low in brain penetration, and are hence useful as asthma preventives and curatives.

    摘要翻译: PCT No.PCT / JP98 / 03054 Sec。 371日期1999年3月5日 102(e)1999年3月5日PCT PCT 1998年7月7日PCT公布。 公开号WO99 /​​ 02520 日期1999年1月21日本发明涉及由下式(1)表示的二胺衍生物或其盐。 其中R1表示H,OH,芳烷氧基或卤素原子; R2表示H或低级烷基; A表示-C(R3)= CH-,-CH = N-,-N(R4) - ,R3为H或OH,R4为低级烷基或烷氧基烷基,-O-或-S-; B表示单键,-C(R5)(R6) - (CH2)k-,R5和R6是H或低级烷基,k表示0-2,-S(O)qCH( R7)或-CH = CH-; E表示单键或 - (CH 2)3 - ; W和Y各自表示-CH 2 - 或-CO-; Z表示O或S; m为2或3,n为1〜4的值。 条件是当B是单键时E是 - (CH 2)3,当B是除单键以外的基团时,E是单键。 二胺衍生物或其盐具有抗白细胞增多作用和抗组胺作用,并且脑渗透性低,因此可用作哮喘预防剂和固化剂。

    Flavone derivative and medicine comprising the same
    9.
    发明授权
    Flavone derivative and medicine comprising the same 失效
    黄酮衍生物及其组合物

    公开(公告)号:US6136848A

    公开(公告)日:2000-10-24

    申请号:US942498

    申请日:1997-10-02

    摘要: This invention relates to a flavone derivative represented by the formula (1) or a salt thereof, and also to a medicine containing the same. ##STR1## wherein A represents H, halogen, phenyl, naphthyl, a group of the formula (2) in which X is H or halogen, B is --CH.dbd.CH--, --CH.dbd.N--, --N(R.sup.7)-- (R.sup.7 : lower alkyl or alkoxyalkyl), --O-- or --S--; W represents a single bond, --CH.sub.2 O-- or --CH.dbd.CH--; at least one of R.sup.1 to R.sup.4 represents --COOH, --CN, alkyloxycarbonyl, tetrazolyl or --CONHR.sup.8 (R.sup.8 : H, lower alkyl or phenylsulfonyl), the remainder thereof individually represent H, halogen, --OH, lower alkyl or lower alkoxyl; R.sup.5 represents H, --OH, lower alkoxyl, --O(CH.sub.2).sub.m NR.sup.9 R.sup.10 (R.sup.9,R.sup.10 : H or lower alkyl, or coupled together with the adjacent N to form a phthalimido group; m: 1-5), or a group of the formula (3) (n: 1-5, l: 2-3; and R.sup.6 represents H, halogen, lower alkyl or lower alkoxyl. A situation where A is H or halogen, W is a single bond and R.sup.5 is H is excluded. The compound (1) has excellent cys-LT.sub.1 receptor antagonism.

    摘要翻译: 本发明涉及由式(1)表示的黄酮衍生物或其盐,以及含有该衍生物的药物。 其中A表示H,卤素,苯基,萘基,其中X是H或卤素的式(2)的基团,B是-CH = CH-,-CH = N-,-N(R 7) - (R 7: 低级烷基或烷氧基烷基),-O-或-S-; W表示单键,-CH 2 O-或-CH = CH-; R 1至R 4中的至少一个表示-COOH,-CN,烷氧基羰基,四唑基或-CONHR 8(R 8:H,低级烷基或苯基磺酰基),其余部分分别表示H,卤素,-OH,低级烷基或低级烷氧基; R5表示H,-OH,低级烷氧基,-O(CH2)mNR9R10(R9,R10:H或低级烷基,或与相邻的N一起形成邻苯二甲酰亚氨基; m:1-5)或一组 式(3)(n:1-5,1:2-3; R6表示H,卤素,低级烷基或低级烷氧基),其中A为H或卤素,W为单键,R5为H的情况为 化合物(1)具有优异的cys-LT1受体拮抗作用。

    Pyrimidine derivatives
    10.
    发明授权
    Pyrimidine derivatives 失效
    嘧啶衍生物

    公开(公告)号:US6008224A

    公开(公告)日:1999-12-28

    申请号:US849725

    申请日:1997-06-27

    CPC分类号: C07D239/69

    摘要: The present invention is directed to a pyrimidine derivative of the following formula (1) or a salt of the derivative: ##STR1## [wherein R.sup.1 represents a lower alkyl group; each of R.sup.2 and R.sup.3 represents H, alkyl, or alkoxy; each of R.sup.4 and R.sup.5 represents H or alkyl; R.sup.6 represents alkyl, --OR.sup.7, or --NR.sup.8 R.sup.9 ; and n is a number between 0 and 3 inclusive (wherein each of R.sup.7, R.sup.8, and R.sup.9 represents H, alkyl, aryl, aralkyl, amino, a heterocyclic ring, etc.)], as well as to a medicine containing the derivative or salt as the active ingredient. The present compounds exhibit strong binding inhibitory activity against endothelin having potent vasoconstrictive effect and cell proliferation effect. Therefore, the compounds are effective as remedies for various diseases including circulatory diseases.

    摘要翻译: PCT No.PCT / JP95 / 02605 Sec。 371日期:1997年6月27日 102(e)日期1997年6月27日PCT 1995年12月19日PCT公布。 公开号WO96 / 20177 PCT 日期:1996年7月4日本发明涉及下述式(1)所示的嘧啶衍生物或其衍生物的盐:其中R1表示低级烷基; R 2和R 3各自表示H,烷基或烷氧基; R 4和R 5各自表示H或烷基; R 6表示烷基,-OR 7或-NR 8 R 9; 并且n是0和3之间的数字(其中R7,R8和R9各自表示H,烷基,芳基,芳烷基,氨基,杂环等)],以及含有该衍生物或 盐作为活性成分。 本发明化合物对内皮素具有强烈的结合抑制活性,具有强烈的血管收缩作用和细胞增殖作用。 因此,该化合物作为包括循环系统疾病在内的各种疾病的治疗方法是有效的。